Compare IMKTA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | HRMY |
|---|---|---|
| Founded | 1963 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | IMKTA | HRMY |
|---|---|---|
| Price | $83.78 | $28.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.70 |
| AVG Volume (30 Days) | 105.4K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | ★ $5,334,032,609.00 | $868,453,000.00 |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | N/A | $12.49 |
| P/E Ratio | $15.91 | ★ $10.28 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $59.09 | $25.52 |
| 52 Week High | $90.49 | $40.87 |
| Indicator | IMKTA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 35.55 |
| Support Level | $68.58 | $27.66 |
| Resistance Level | $90.24 | $28.99 |
| Average True Range (ATR) | 2.55 | 0.81 |
| MACD | -0.51 | 0.23 |
| Stochastic Oscillator | 51.33 | 44.26 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.